^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate) + saruparib (AZD5305) (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1142 / 6 - Activity and tolerability of combination of trastuzumab deruxtecan with the next generation PARP1-selective inhibitor AZD5305 in preclinical models
Published date:
03/09/2022
Excerpt:
We found that reducing the dose of AZD5305 as low as 0.01mg/kg resulted in combination benefit (100% TGI with 78% regression for combination versus 0% TGI for monotherapy on day 30). Further, 7-day delay of 0.01mg/kg AZD5305 in combination with 10mg/kg T-DXd also provided greater activity (>100% TGI with 72% regression on day 30) vs. monotherapy T-DXd alone (95% TGI). These results suggest that T-DXd combined with the next generation PARP1 inhibitor AZD5305 is a potentially active combination, with preclinical activity demonstrated in HRD and HR proficient models.
